Trials / Recruiting
RecruitingNCT06770569
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
A Single-arm, Open-Label, Multi-center Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-3802 | HRS-3802 |
Timeline
- Start date
- 2025-01-21
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-01-13
- Last updated
- 2026-03-30
Locations
6 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT06770569. Inclusion in this directory is not an endorsement.